Cross‐sectional study of therapy‐related expectations/concerns of patients with metastatic renal cell carcinoma and physicians in Japan
Cancer Medicine · 2024
DOI: 10.1002/cam4.7196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Go Kimura und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nippon Medical School Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eisai Co., Ltd., Eisai Canada.
Abstract (Originalsprache)
Objective
To achieve patient‐centricity in metastatic renal cell carcinoma (mRCC) treatment, it is essential to clarify the differences in perspectives between patients and physicians. This cross‐sectional analysis of a web survey aimed to clarify the differences in expectations and concerns between mRCC patients and physicians regarding systemic mRCC therapy in Japan.
Methods
Surveys from 83 patients and 165 physicians were analyzed.
Results
The top three most significant differences in expectations of systemic therapy between patients and physicians (patient‐based physician value) were “Chance of achieving treatment‐free status” (−30.1%, p < 0.001), “Longer survival” (+25.8%, p < 0.001), and “Chance of eliminating all evidence of disease” (−25.6%, p < 0.001). The top three most significant differences in concerns for systemic therapy between patients and physicians (patient‐based physician value) were “Lack of efficacy” (+36.1%, p < 0.001), “Lack of knowledge of treatment” (−28.2%, p < 0.001), and “Daily activities affected by side effects” (+22.3%, p < 0.001). Diarrhea, fatigue/malaise, and nausea/vomiting were patients' most distressing adverse events; 50.6% of patients had difficulty telling their physicians about adverse events such as fatigue, anxiety, and depression.
Conclusions
This study demonstrated a gap between patients with mRCC and physicians in their expectations and concerns for systemic therapy. Japanese patients with mRCC suffer from a number of adverse events, some of which are not shared with physicians. This study highlights the importance of communicating well with patients in clinical practice to achieve patient‐centricity in systemic treatment for mRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Nippon Medical School Hospital, Tokyo, Japan.
- Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
- Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, Tokyo, Japan.
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan.
- Department of Nursing, National Cancer Center Hospital East, Kashiwa, Japan.
ORCID-Profile: Go Kimura, Yasuhisa Fujii, Nobuo Shinohara
Förderung
- Eisai Co., Ltd.
- Eisai Canada
Zitieren
APA
Kimura, G., Fujii, Y., Osawa, T., Uchitomi, Y., Honda, K., Kondo, M., Otani, A., Wako, T., Kawai, D., Mitsuda, Y., Sakashita, N., & Shinohara, N. (2024). Cross‐sectional study of therapy‐related expectations/concerns of patients with metastatic renal cell carcinoma and physicians in Japan. Cancer Medicine. https://doi.org/10.1002/cam4.7196
Vancouver
Kimura G, Fujii Y, Osawa T, Uchitomi Y, Honda K, Kondo M, et al. Cross‐sectional study of therapy‐related expectations/concerns of patients with metastatic renal cell carcinoma and physicians in Japan. Cancer Medicine. 2024. doi:10.1002/cam4.7196
BibTeX
@article{Kimura2024,
author = {Kimura, Go and Fujii, Yasuhisa and Osawa, Takahiro and Uchitomi, Yosuke and Honda, Kazunori and Kondo, Miki and Otani, Ariko and Wako, Tetsuya and Kawai, Daisuke and Mitsuda, Yoshihide and Sakashita, Naotaka and Shinohara, Nobuo},
title = {Cross‐sectional study of therapy‐related expectations/concerns of patients with metastatic renal cell carcinoma and physicians in Japan},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7196}
}
EUVIMED